LensGen Will Present Early Results Of International “Grail” Study At ASCRS
LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego,May 3-7. The results will include the latest available data on patients who have been treated at two international sites.
Juvene is the world’s first modular fluid optic IOL that uses biomimetic design principals to emulate the natural crystalline lens and provide a continuous range of vision, dynamically from distance to near with high quality optics.
“We at LensGen are excited that this innovative technology is generating excellent early outcomes in the “Grail” study,” Ramgopal Rao, LensGen Founder and Chief Executive Officer, said in a company news release. “As we prepare for FDA clinical trials, we are gratified that early data from the “Grail” study is supporting several benefits of our platform technology.”
LensGen Scientific Adviser Featured
Each year, the American Society of Cataract and Refractive Surgery (ASCRS) honors individuals whose innovative ideas have benefited ophthalmologists and their patients. A member of the company’s Scientific Advisory Board will be one of five persons featured at the ASCRS Innovators Lecture on Monday May 6.
Eric Donnenfeld, MD, is an internationally recognized expert and pioneer in refractive, cornea and cataract surgery, a past ASCRS President and one of the leading cataracts and refractive surgeons in the United States. In his lecture, he will discuss the Juvene technology and present the early data.
“The Juvene implant is designed to change curvature like the natural human lens and show it can rejuvenate youthful vision to individuals affected by cataracts and presbyopia,” Dr. Donnenfeld said in a company news release. “I look forward to sharing more information about this potential game changing innovation.”
LensGen To Be Featured in Refractive Subspecialty Day
Uday Devgan, MD, will be speaking about the Juvene in a session at the ASCRS Subspecialty Day on Friday, May 3. The session will be moderated by Rosa Braga-Mele, MD.
“The company has developed a very safe, innovative product that will be intuitive to cataract and refractive surgeons and that has the potential to revolutionize how we treat cataracts and presbyopia,” said Dr. Devgan., a leading surgeon who founded Devgan Eye Surgery in Los Angeles, California and is Clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine.
Technology, Surgical Procedure and Future Opportunities
The company also plans to share additional information to selected surgeons and other interested parties on the evening of May 3, where Dr. Donnenfeld will discuss the technology, Dr. Devgan will review the surgical procedure and Sumit (Sam) Garg, MD, who is Medical Director and an Associate Professor in Cataract, Refractive, External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at the University of California, Irvine, will address the future potential of the technology.
Dr. Braga-Mele, Dr. Devgan, Dr. Donnenfeld, and Dr. Garg are all LensGen Scientific Advisers.